Second-line switch to dolutegravir noninferior in HIV

For patients with HIV without genotype information, a second-line switch to dolutegravir is noninferior to a regimen containing a ritonavir-boosted protease inhibitor (PI), according to a study published in the June 22 issue ...


Easy-to-take medicine better at suppressing HIV in children

A once-a-day antiretroviral medicine that is low-cost and easy for children to take is also more effective at suppressing HIV than standard treatments, according to a global trial led by researchers at UCL.

page 1 from 2